Paracetamol is used as a complimentary painrelief. Using sealed envelopes, 140 patients will be randomly assigned to receive either 1g paracetamol as tablets (Panodil® Glaxo Smith Kline) or 1g placebo every 6th hour after heartsurgery for 3 days. The occurrence of postoperative nausea will be assessed. Pain will be evaluated. The total amount of opioids will be noted and calculated. After the study we will break the code with sealed envelopes. MedDRA version: 9.1 Level: LLT Classification c
Conditions
Interventions
Trade Name: Panodil (paracetamol)
Product Name: Paracetamol
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Sponsors
Karolinska Universitetssjukhuset Solna
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 140 patients , undergoing heart surgery will be randomised upon arrival to the intensive care unit to receive either paracetamol every 6th hour or placebo. 18 years and older. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients not suited for paracetamol. Non conversationable. Women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Will paracetamol reduce the opioid requirements and the (opioid)related postoperative nausea? ;Secondary Objective: Will paracetamol reduce PONV (postoperative nausea and vomiting) and pain?;Primary end point(s): Will paracetamol reduce opioid requirements and also the opioid related nausea without increased pain. | — |
Countries
Sweden
Outcome results
None listed